TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) announced that it will reveal topline results from the Tollovir™ Phase 2 clinical trial for hospitalized COVID-19 patients on January 27, 2022. A conference call will follow the announcement after market close. Todos Medical's joint venture with NLC Pharma focuses on COVID-19 diagnostic solutions, and the company is also developing diagnostic tests for neurodegenerative diseases like Alzheimer’s. The data lock for the trial will be announced the week ending January 17, 2022.

Todos Medical, Ltd. (OTCQB: TOMDF) announced CEO Gerald Commissiong's appearance on Fox Business’ The Claman Countdown on January 11, 2022, discussing COVID testing in the U.S. and the anticipated Phase 2 results of Tollovir™, a 3CL protease inhibitor for COVID-19 treatment. Additionally, a blog titled “COVID Testing: What Needs to Happen Now to Turn the Corner in 2022” was released, addressing improvements needed in U.S. COVID testing infrastructure. The Company is also participating in the virtual Biotech Showcase 2022 from January 10-12, 2022.

Todos Medical, Ltd. (OTCQB: TOMDF) announced plans for a national exchange listing in 2022. The company is finalizing the acquisition of NLC Pharma assets and has made progress in developing COVID-related diagnostics and therapeutics. Recent record sales of its Tollovid products reflect growing demand for 3CL protease inhibitors. Ongoing clinical trials for Tollovir and proprietary tests for breast cancer (Videssa) and Alzheimer’s (LymPro) are in progress, with significant data expected by January 26, 2022. The company aims for Emergency Use Authorization for its products in multiple jurisdictions.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced that its President & CEO, Gerald Commissiong, will present at the Emerging Growth Conference on January 5, 2022, at 12:00 PM EST. This interactive online event allows shareholders and the investment community to engage directly with the CEO. Todos Medical is known for its innovative diagnostic solutions for early cancer detection and has developed proprietary technologies such as the Todos Biochemical Infrared Analyses. The company has also acquired Provista Diagnostics, enhancing its capabilities in medical diagnostics.

Todos Medical, Ltd. (OTCQB: TOMDF) has reported record weekly COVID PCR testing volumes in mid-December 2021, attributed to increased demand amid the ongoing pandemic. The company has signed a laboratory services agreement with a New Jersey physician practice for both PCR and cPass neutralizing antibody testing. The CEO anticipates sustained demand for testing due to low vaccination rates and new mandates. Additionally, interest in cPass testing is rising as people seek to monitor their immunity against variants like Omicron.

Todos Medical (OTCQB: TOMDF) announces CEO Gerald Commissiong will discuss COVID-19 testing and their oral antiviral Tollovir™ on Yahoo Finance Live and BNC. Tollovir™ is in Phase 2 clinical trials for hospitalized COVID patients. The company, based in Israel and New York, focuses on diagnostics for cancer and COVID-19, including PCR testing and proprietary cancer-screening technologies. Todos aims to commercialize its cancer tests alongside the ongoing development of Tollovir™ amidst the growing landscape of COVID-19 treatments, including Pfizer's Paxlovid.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced that its Provista Diagnostics laboratory has secured a reference laboratory services agreement with a physician group across 40 states. The agreement encompasses the expanded semi-quantitative cPass neutralizing antibody test capable of measuring convalescent neutralization activity. Additionally, Provista has validated an At-Home fingerprick sample collection device for the cPass test, enhancing convenience for consumers. CEO Gerald E. Commissiong noted the test's growing importance amidst the Omicron variant and waning immunity.

Todos Medical (OTCQB: TOMDF) has appointed Valentino Smith, MBA, as Vice President of Marketing, bringing over ten years of experience in healthcare marketing. The company has also partnered with iiiNTENT, an AI marketing service, to enhance the promotion of its products, Tollovid® and Tollovid Daily™, aimed at providing immune support. The leadership change and marketing collaboration come as Todos Medical anticipates a significant increase in demand for COVID-19 related products and services, particularly during the Omicron variant surge and as its antiviral candidate, Tollovir™, progresses in clinical trials.

Todos Medical Ltd. (OTCQB: TOMDF) has launched the 'Test & Tollovid®' Holiday Package in Atlanta, priced at $329. This package includes a bottle of maximum strength Tollovid and an at-home COVID-19 PCR test kit. Customers can return samples via prepaid FedEx or drop them off at the lab for quicker results. The company aims to enhance its testing capabilities while promoting its therapeutic candidate, Tollovir™, currently in a Phase 2 clinical trial.